Topics in Clinical Microbiology

Over the last 30 years, Serratia marcescens has become an important cause of nosocomial infection. There have been many reports concerning the identification, antibiotic susceptibility, pathogenicity, epidemiological investigations and typing of this organism. Accurate identification is important in defining outbreaks. The API 20E system has been used widely, but is not individually satisfactory. The growth of S. marcescens in the environment has been investigated in relation to water, disinfectants and plastics such as blood bags. Certain extracellular products are unique to S. marcescens. Pigment (prodigiosin) biosynthesis by S. marcescens has been investigated fully since the emergence of the organism as a cause of infection. Many other aspects of the pathogenicity and virulence of S. marcescens have been studied, including adherence and hydrophobicity, lipopolysaccharide (LPS) and extracellular products. Two modes of adhesion to host epithelial surfaces have been suggested. These are mannose-resistant (MR) pili and mannose-sensitive (MS) pili. LPS, which is responsible for the biological activity of endotoxin, has been investigated fully and 24 somatic antigens have been described. The production of different enzymes by S. marcescens as virulence factors has also been reported, including chitinase, lipase, chloroperoxidase and an extracellular protein, HasA. Antibiotics used to treat serratia infection include beta-lactam agents, aminoglycosides and fluoroquinolones and a variety of different resistance mechanisms have been demonstrated. Typing methods used to study the epidemiology of S. marcescens include biotyping, bacteriocin typing, phage typing, plasmid analysis, polymerase chain reaction amplification of enterobacterial repetitive intergenic consensus sequences (ERIC-PCR) and ribotyping. Serological typing has also been used and this method seems to be a suitable first-line typing method for S. marcescens, although some strains remain untypable. RAPD-PCR has also been applied to a small number of isolates and seems to be a promising method, especially for rapid monitoring of an outbreak and tracing the source of initial infection.

[1]  D. Straus,et al.  Importance of a lipopolysaccharide-containing extracellular toxic complex in infections produced by Klebsiella pneumoniae , 1985, Infection and immunity.

[2]  K. Omori,et al.  The three genes lipB, lipC, and lipD involved in the extracellular secretion of the Serratia marcescens lipase which lacks an N-terminal signal peptide , 1995, Journal of bacteriology.

[3]  W. Martone,et al.  Epidemic septic arthritis caused by Serratia marcescens and associated with a benzalkonium chloride antiseptic , 1987, Journal of clinical microbiology.

[4]  D. Livermore,et al.  Characterization of an LysR family protein, SmeR from Serratia marcescens S6, its effect on expression of the carbapenem-hydrolyzing beta-lactamase Sme-1, and comparison of this regulator with other beta-lactamase regulators , 1995, Antimicrobial agents and chemotherapy.

[5]  R. Hancock,et al.  Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells , 1991, Antimicrobial Agents and Chemotherapy.

[6]  R. P. Williams,et al.  Induction of Pigmentation in Nonproliferating Cells of Serratia marcescens by Addition of Single Amino Acids , 1971, Journal of bacteriology.

[7]  I. Slotki,et al.  Prevention of scarring in experimental pyelonephritis in the rat by early antibiotic therapy. , 1982, Nephron.

[8]  P. Gerner-Smidt,et al.  Nosocomial epidemic of Serratia marcescens septicemia ascribed to contaminated blood transfusion bags , 1993, Transfusion.

[9]  Y. Xiong,et al.  In vivo bactericidal activities of ciprofloxacin and pefloxacin in an experimental model of Serratia marcescens endocarditis , 1994, Antimicrobial Agents and Chemotherapy.

[10]  F. Grimont,et al.  Ribosomal ribonucleic acid gene restriction patterns as potential taxonomic tools. , 1986, Annales de l'Institut Pasteur. Microbiology.

[11]  C. Henquell,et al.  Clinical and bacteriological study of nosocomial infections due to Enterobacter aerogenes resistant to imipenem , 1993, Journal of clinical microbiology.

[12]  S. Létoffé,et al.  Identification of two components of the Serratia marcescens metalloprotease transporter: protease SM secretion in Escherichia coli is TolC dependent , 1993, Journal of bacteriology.

[13]  C. Watanakunakorn,et al.  Emergence of resistance to imipenem in Enterobacter isolates masquerading as Klebsiella pneumoniae during therapy with imipenem/cilastatin. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Rosenberg,et al.  Effect of Cetylpyridinium Chloride on Microbial Adhesion to Hexadecane and Polystyrene , 1990, Applied and environmental microbiology.

[15]  A. Hejazi,et al.  The use of RAPD-PCR as a typing method for Serratia marcescens. , 1997, Journal of medical microbiology.

[16]  A. Wardlaw,et al.  Growth and survival of Bordetella bronchiseptica in natural waters and in buffered saline without added nutrients , 1991, Applied and environmental microbiology.

[17]  H. Chetoui,et al.  Ribotyping for use in studying molecular epidemiology of Serratia marcescens: comparison with biotyping , 1995, Journal of clinical microbiology.

[18]  Y. Mizunoe,et al.  Effect of pili of Serratia marcescens on superoxide production and phagocytosis of human polymorphonuclear leukocytes. , 1995, The Journal of urology.

[19]  M. Viñas,et al.  The role of O-antigen in susceptibility of Serratia marcescens to non-immune serum. , 1993, Microbios.

[20]  J. Billé,et al.  Protection against chronic pyelonephritis in rats by suppression of acute suppuration: effect of colchicine and neutropenia. , 1982, The Journal of infectious diseases.

[21]  P S Cohen,et al.  Infective endocarditis caused by gram-negative bacteria: a review of the literature, 1945-1977. , 1980, Progress in cardiovascular diseases.

[22]  Claude Carbón Impact of the antibiotic dosage schedule on efficacy in experimental endocarditis. , 1990, Scandinavian journal of infectious diseases. Supplementum.

[23]  R. Harshey,et al.  Mutations that impair swarming motility in Serratia marcescens 274 include but are not limited to those affecting chemotaxis or flagellar function , 1992, Journal of bacteriology.

[24]  C. Kunin,et al.  Control of a single source nursery epidemic due to Serratia marcescens. , 1966, Pediatrics.

[25]  A. Bisno,et al.  Epidemic Serratia marcescens in a Neonatal Intensive Care Unit: Importance of the Gastrointestinal Tract as a Reservoir , 1982, Infection Control.

[26]  R. Coria-Jiménez,et al.  Aminoglycoside resistance patterns of Serratia marcescens strains of clinical origin , 1994, Epidemiology and Infection.

[27]  L. Papazian,et al.  A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care. , 1993, The Journal of antimicrobial chemotherapy.

[28]  J. Hows,et al.  Ciprofloxacin resistant Serratia marcescens endocarditis as a complication of non-Hodgkin's lymphoma. , 1994, The Journal of infection.

[29]  A. Zuckerman,et al.  INFECTION DUE TO CHROMOBACTERIA: Report of Eleven Cases , 1951 .

[30]  M. Silverman,et al.  Effect of Iron and Salt on Prodigiosin Synthesis in Serratia marcescens , 1973, Journal of bacteriology.

[31]  E. Reese,et al.  The chitinase of Serratia marcescens. , 1969, Canadian journal of microbiology.

[32]  V L Yu,et al.  Serratia marcescens: historical perspective and clinical review. , 1979 .

[33]  A. Bhasin,et al.  Mutational analysis of flagellum-independent surface spreading of Serratia marcescens 274 on a low-agar medium , 1995, Journal of Bacteriology.

[34]  W. J. Martin,et al.  Serratia marcescens: Biochemical Characteristics, Antibiotic Susceptibility Patterns, and Clinical Significance , 1970 .

[35]  D. Oxley,et al.  Structures of neutral glycans isolated from the lipopolysaccharides of reference strains for Serratia marcescens serogroups O16 and O20. , 1989, Carbohydrate research.

[36]  D. Sordelli,et al.  An 8-year study of resistance to amikacin in gram-negative bacilli isolates from patients with nosocomial infection at one hospital in Argentina. , 1995, Journal of medical microbiology.

[37]  O. Kwon,et al.  In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli. , 1993, The Journal of antimicrobial chemotherapy.

[38]  S. Mudd,et al.  THE PENETRATION OF BACTERIA THROUGH CAPILLARY SPACES : IV. A KINETIC MECHANISM IN INTERFACES. , 1924 .

[39]  W. Traub Serotyping of Serratia marcescens: detection of two new O-antigens (O25 and O26). , 1991, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

[40]  T. Stenström,et al.  Growth and survival of Serratia marcescens under aerobic and anaerobic conditions in the presence of materials from blood bags , 1993, Journal of clinical microbiology.

[41]  R. Sautter,et al.  Serratia Marcescens Meningitis Associated With a Contaminated Benzalkonium Chloride Solution , 1984, Infection Control.

[42]  P. Nordmann,et al.  Biochemical properties of a carbapenem-hydrolyzing beta-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli , 1993, Antimicrobial Agents and Chemotherapy.

[43]  R. Fuchs,et al.  Cloning of a Serratia marcescens Gene Encoding Chitinase , 1986, Applied and environmental microbiology.

[44]  C. Hogman,et al.  The role of white cells in the transmission of Yersinia enterocolitica in blood components , 1992, Transfusion.

[45]  J. Costerton,et al.  Prolonged survival of Serratia marcescens in chlorhexidine , 1981, Applied and environmental microbiology.

[46]  R. P. Williams,et al.  Influence of Temperature of Incubation and Type of Growth Medium on Pigmentation in Serratia marcescens , 1971, Journal of bacteriology.

[47]  G. Ihler,et al.  Genetic analysis of extracellular proteins of Serratia marcescens , 1988, Journal of bacteriology.

[48]  J. Sleigh Antibiotic resistance in Serratia marcescens. , 1983, British medical journal.

[49]  D. Woodfield Transfusion acquired Serratia liquefaciens septicaemia. , 1991, The New Zealand medical journal.

[50]  D. Livermore,et al.  Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6 , 1994, Antimicrobial Agents and Chemotherapy.

[51]  J. Tsang,et al.  Enhancement by Sodium Dodecyl Sulfate of Pigment Formation in Serratia marcescens O8 , 1982, Applied and environmental microbiology.

[52]  C. Whitfield,et al.  Relationships between rfb gene clusters required for biosynthesis of identical D-galactose-containing O antigens in Klebsiella pneumoniae serotype O1 and Serratia marcescens serotype O16 , 1995, Journal of bacteriology.

[53]  T. Pitt,et al.  Improved O-serotyping method for Serratia marcescens , 1989, Journal of clinical microbiology.

[54]  E. G. Allen Conditions of the Colour Change of Prodigiosin , 1967, Nature.

[55]  D Drew,et al.  Serratia marcescens endocarditis: a regional illness associated with intravenous drug abuse. , 1976, Annals of internal medicine.

[56]  C. Hogman,et al.  Transfusion‐associated Serratia marcescens infection: studies of the mechanism of action , 1993, Transfusion.

[57]  M. Walder,et al.  Persistance of Serratia marcescens, Serratia liquefaciens and E. coli in solutions for contact lenses , 1986, Acta ophthalmologica.

[58]  J. Sobel,et al.  Bacterial adherence in the pathogenesis of urinary tract infection: a review. , 1987, Reviews of infectious diseases.

[59]  Y. Arakawa,et al.  Plasmid-mediated dissemination of the metallo-beta-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens , 1995, Antimicrobial agents and chemotherapy.

[60]  K. van Pée,et al.  Purification and properties of a non-haem chloroperoxidase from Serratia marcescens. , 1995, FEMS microbiology letters.

[61]  R. Harshey,et al.  Differentiation of Serratia marcescens 274 into swimmer and swarmer cells , 1990, Journal of bacteriology.

[62]  E. Denamur,et al.  Ribotyping provides efficient differentiation of nosocomial Serratia marcescens isolates in a pediatric hospital , 1992, Journal of clinical microbiology.

[63]  N. J. Ehrenkranz,et al.  ANTIBIOTIC-SENSITIVE SERRATIA MARCESCENS INFECTIONS COMPLICATING CARDIOPULMONARY OPERATIONS: CONTAMINATED DISINFECTANT AS A RESERVOIR , 1980, The Lancet.

[64]  S. Létoffé,et al.  Secretion of the Serratia marcescens HasA protein by an ABC transporter , 1994, Journal of bacteriology.

[65]  C. Hogman,et al.  White cells protect donor blood against bacterial contamination , 1991, Transfusion.

[66]  C. Cox Aztreonam therapy for complicated urinary tract infections caused by multidrug-resistant bacteria. , 1985, Reviews of infectious diseases.

[67]  R. Charrel,et al.  Serratia marcescens nosocomial outbreak due to contamination of hexetidine solution. , 1996, The Journal of hospital infection.

[68]  N. Kaplan,et al.  DNA from Serratia marcescens confers a hydrophobic character in Escherichia coli. , 1995, FEMS microbiology letters.

[69]  R. Wenzel,et al.  Catheter-associated bacteriuria. Failure to reduce attack rates using periodic instillations of a disinfectant into urinary drainage systems. , 1984 .

[70]  A. Ellingboe,et al.  Molecular cloning of two chitinase genes from Serratia marcescens and their expression in Pseudomonas species , 1988 .

[71]  M. Viñas,et al.  Serratia marcescens adherence: the effect of O-antigen presence. , 1995, Microbios.

[72]  K. Livak,et al.  DNA polymorphisms amplified by arbitrary primers are useful as genetic markers. , 1990, Nucleic acids research.

[73]  D. Craven,et al.  Serratia marcescens contamination of antiseptic soap containing triclosan: implications for nosocomial infection. , 1984, Infection control : IC.

[74]  I. N. Andreeva,et al.  Effect of various growth conditions on pigmentation of Serratia marcescens. , 1994, Microbios.

[75]  W. Liu,et al.  Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents , 1990, Antimicrobial Agents and Chemotherapy.

[76]  T. Pitt,et al.  O-antigen specificities of the serotype strains of Serratia marcescens , 1989, Journal of clinical microbiology.

[77]  F. Baquero,et al.  Comparison of serotype, biotype and bacteriocin type with rDNA RFLP patterns for the type identification of Serratia marcescens , 1993, Epidemiology and Infection.

[78]  A. P. Ball,et al.  Serratia marcescens in a general hospital. , 1977, The Quarterly journal of medicine.

[79]  F. Grimont,et al.  Nosocomial Serratia marcescens individualized by five typing methods in a regional hospital. , 1990, The Journal of hospital infection.

[80]  W. Blakemore,et al.  Serratia marcescens. A pathogen of increasing clinical importance. , 1970, JAMA.

[81]  T. Pitt,et al.  Infection with netilmicin resistant Serratia marcescens in a special care baby unit. , 1983, British medical journal.

[82]  F. Grimont,et al.  Biotyping of Serratia marcescens and its use in epidemiological studies , 1978, Journal of clinical microbiology.

[83]  M. Cheung,et al.  Use of PCR to study epidemiology of Serratia marcescens isolates in nosocomial infection , 1994, Journal of clinical microbiology.

[84]  K. Kaneda,et al.  A novel extracellular cyclic lipopeptide which promotes flagellum-dependent and -independent spreading growth of Serratia marcescens , 1992, Journal of bacteriology.

[85]  W. Martone,et al.  Survival of Serratia marcescens in benzalkonium chloride and in multiple-dose medication vials: relationship to epidemic septic arthritis , 1987, Journal of clinical microbiology.

[86]  F. Yoshimura,et al.  Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance , 1994, Antimicrobial Agents and Chemotherapy.

[87]  P. Hawkey,et al.  Selection of netilmicin resistance, associated with increased 6' aminoglycoside acetyltransferase activity, in Serratia marcescens. , 1988, The Journal of antimicrobial chemotherapy.

[88]  J M Lyons,et al.  Prevention of chronic experimental pyelonephritis by suppression of acute suppuration. , 1978, The Journal of clinical investigation.

[89]  K. A. Merendino,et al.  Serratia marcescens endocarditis. A review of the literature and report of a case involving a homograft replacement of the aortic valve. , 1969, Archives of surgery.

[90]  V. Eijsink,et al.  Characterization of a chitinase gene (chiA) from Serratia marcescens BJL200 and one-step purification of the gene product. , 1994, FEMS microbiology letters.

[91]  M. Rosenberg,et al.  Mechanism of enhancement of microbial cell hydrophobicity by cationic polymers , 1990, Journal of bacteriology.

[92]  K. Joiner Studies on the mechanism of bacterial resistance to complement-mediated killing and on the mechanism of action of bactericidal antibody. , 1985, Current topics in microbiology and immunology.

[93]  M. Rosenberg,et al.  Cell surface hydrophobicity of pigmented and nonpigmented clinical Serratia marcescens strains , 1986, Infection and immunity.

[94]  I. Yano,et al.  Extracellular Vesicle Formation and Biosurfactant Production by Serratia marcescens , 1986 .

[95]  T. Pitt State of the art: typing of Serratia marcescens. , 1982, The Journal of hospital infection.

[96]  M. Viñas,et al.  Lipopolysaccharide recovery restores susceptibility levels towards beta-lactams in Serratia marcescens. , 1995, Microbios.